Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oral Microalgae-Based Biosystem to Enhance Irreversible Electroporation Immunotherapy in Hepatocellular Carcinoma.
Adv Sci (Weinh)
January 2025
Department of Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Irreversible electroporation (IRE) is a novel local tumor ablation technique that can potentially stimulate immune responses. However, IRE alone cannot effectively activate the immune system or prevent distant metastases. Therefore, this study utilized the biocompatibility of Chlorella vulgaris (C.
View Article and Find Full Text PDFβ2-Adrenergic Receptor Agonist Clenbuterol Protects Against Acute Ischemia/Reperfusion-Induced Arrhythmia by Regulation of Akt/eNOS/NO/Cx43 Signaling Pathway.
Pharmacol Res Perspect
February 2025
Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ventricular arrhythmias induced by ischemia/reperfusion injury limits the therapeutic effect of early reperfusion therapy for acute myocardial infarction. This study investigated the protective effects of the β2-adrenergic receptor (β2-AR) agonist clenbuterol against ischemia/reperfusion-induced arrhythmias and the underlying mechanism. Anesthetized rats were subjected to 10-min left coronary artery occlusion and 10-min reperfusion in vivo.
View Article and Find Full Text PDFInavolisib: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.
View Article and Find Full Text PDFCytokinin negatively regulates tomato fruit ripening by influencing the ethylene pathway.
Plant Cell Rep
January 2025
College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China.
Reducing endogenous CK levels accelerates fruit ripening in tomato by regulating ethylene biosynthesis and signalling pathway. Tomato is a typical climacteric fruit and is recognized as one of the most important horticultural crops globally. The ripening of tomato fruits is a complex process, highly regulated by phytohormones.
View Article and Find Full Text PDFOptimized nanostructured lipid carriers from aceh traditional coconut (Pliek) oil: a promising topical formulations for atopic dermatitis.
Arch Dermatol Res
January 2025
Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia.
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by dry skin, severe itching, redness, and inflammation. Its complex etiology, involving genetic, immunological, and environmental factors, necessitates innovative therapeutic approaches. This study investigates nanostructured lipid carriers (NLCs) formulated with traditional fermented coconut (Cocos nucifera L.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!